SUPN
Supernus Pharmaceuticals Inc
Halal Rating :
Last Price
$37.72
Last updated:
Market Cap
-
7D Change
0.4%
1 Year Change
32.77%
Company Overview
Industries
Exchange
Next Earnings Date
Supernus Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company's main product portfolio includes medications for epilepsy, Parkinson's disease, and attention deficit hyperactivity disorder (ADHD). Their business model revolves around developing and marketing pharmaceutical products that address significant unmet medical needs.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $175.69m | $134.84m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $168.32m | $145.76m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $143.64m | $146.8m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Supernus Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.